PDCD1 and diabetes mellitus: The development of ICI-DM is associated with the introduction of immunotherapy, most notably PD-1 and PD-L1 agents, and is seen after the first three cycles of treatment or within 9 weeks of immunotherapy exposure [4,5,6,7,12].